The complementary action of angiotensin converting enzyme inhibitors and diuretics in the treatment of @entity101 has been demonstrated in a number of studies of @entity10959 and @entity918 ( @entity918 ). The combination provides a clinically significant reduction in blood pressure while minimizing the dose-dependent adverse effects of @entity918 , such as @entity551 and its metabolic effects on plasma lipoproteins, by keeping the dose of each agent to the minimum. @entity10959 has a unique dual mechanism of elimination and can therefore be used in @entity1 with @entity8 . The efficacy of the combination of @entity10959 and @entity918 compared with placebo and other agents is reviewed in this article. Studies have demonstrated that the combination is effective in the elderly and in @entity8 @entity1 , regardless of severity. In addition, in @entity2175 , antihypertensive effect is achieved without further affecting @entity1735 and lipid metabolism, which is often the case when @entity2740 diuretics alone are used. A matrix study was performed to evaluate the optimum dose combination to produce blood pressure normalization and minimize side effects. This study evaluated 17 different dose combinations and demonstrated that the lowest dose combination to produce a clinically significant effect was @entity10959 10 mg and @entity918 12.5 mg. However, a dose-related antihypertensive effect can be seen, giving the option for the use of 20 mg @entity10959 for moderately @entity101 @entity1 . Both combination therapy and @entity10959 were significantly more effective than @entity918 alone or placebo. The @entity10959 / @entity918 combination has also been shown to have a comparable effect to sustained-release @entity594 and @entity1169 + @entity918 . The studies reviewed here demonstrate that @entity10959 / @entity918 combination treatment has a number of advantages over either agent used alone, providing blood pressure normalization in a broad range of @entity101 @entity1 , including @entity6 @entity1 and the elderly.

Management of XXXX : the role of combination therapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2175 :: ('MESH:D003924', 'Disease') :: ['non-insulin dependent diabetes'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renally impaired', 'renal impairment'] @entity1169 :: ('MESH:D011433', 'Chemical') :: ['propanolol'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic'] @entity918 :: ('MESH:D006852', 'Chemical') :: ['HCTZ', 'hydrochlorothiazide'] @entity10959 :: ('MESH:D017328', 'Chemical') :: ['fosinopril', 'Fosinopril'] @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate'] @entity2740 :: ('CHEBI:50264', 'Chemical') :: ['thiazide'] @entity594 :: ('MESH:D009543', 'Chemical') :: ['nifedipine'] @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']
@entity101 :: (MESH:D006973,Disease) :: ['hypertension']
